CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Coherus Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Coherus Biosciences Inc
C/O DENNIS M. LANFEAR
201 REDWOOD SHORES PARKWAY, SUITE 200
Phone: (650) 649-3530p:650 649-3530 REDWOOD CITY, CA  94065  United States Ticker: CHRSCHRS
Business Summary
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Dennis M.Lanfear 68 2/1/2016 9/1/2010
Chief Financial Officer BryanMcmichael 45 8/1/2024 12/8/2023
Chief Development Officer Theresa M.Lavallee 53 12/17/2021 12/17/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Surface Oncology Inc 50 Hampshire Street, 8Th Floor CAMBRIDGE MA United States

Business Names
Business Name
CHRS
Surface Oncology Inc
Surface Oncology, LLC

General Information
Number of Employees: 235 (As of 9/30/2024)
Outstanding Shares: 115,213,407 (As of 10/31/2024)
Shareholders: 85
Stock Exchange: NASD
Federal Tax Id: 273615821
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024